ERIS Lifesciences Ltd Q3FY25; 14% fall in Profits

ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products.

Financial Results:

ERIS Lifesciences Ltd reported Revenues for Q3FY25 of ₹727.00 Crores up from ₹486.00 Crore year on year, a rise of 49.59%.

Total Expenses for Q3FY25 of ₹615.00 Crores up from ₹375.00 Crores year on year, a rise of 64.0%.

Consolidated Net Profit of ₹87.00 Crores down 13.86% from ₹101.00 Crores in the same quarter of the previous year.

The Earnings per Share is ₹6.14, down 18.68% from ₹7.55 in the same quarter of the previous year.